Victory Capital Management Inc. Trims Stock Holdings in Amedisys, Inc. (NASDAQ:AMED)

Victory Capital Management Inc. reduced its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 2.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,088 shares of the health services provider’s stock after selling 182 shares during the period. Victory Capital Management Inc.’s holdings in Amedisys were worth $553,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Westchester Capital Management LLC grew its position in Amedisys by 9.5% in the third quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider’s stock worth $107,976,000 after acquiring an additional 97,476 shares in the last quarter. Geode Capital Management LLC grew its position in Amedisys by 1.3% in the third quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after acquiring an additional 7,071 shares in the last quarter. Pacer Advisors Inc. grew its position in Amedisys by 11,621.9% in the fourth quarter. Pacer Advisors Inc. now owns 558,197 shares of the health services provider’s stock worth $50,679,000 after acquiring an additional 553,435 shares in the last quarter. Calamos Advisors LLC grew its position in Amedisys by 22.7% in the fourth quarter. Calamos Advisors LLC now owns 487,444 shares of the health services provider’s stock worth $44,255,000 after acquiring an additional 90,097 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Amedisys by 4.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 361,812 shares of the health services provider’s stock worth $32,849,000 after acquiring an additional 15,730 shares in the last quarter. 94.36% of the stock is currently owned by hedge funds and other institutional investors.

Amedisys Stock Performance

Shares of NASDAQ:AMED opened at $92.38 on Friday. The company has a market cap of $3.03 billion, a price-to-earnings ratio of 36.66, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76. The company has a 50-day moving average price of $92.21 and a 200-day moving average price of $92.63. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm had revenue of $598.05 million for the quarter, compared to the consensus estimate of $602.38 million. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens reissued an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Amedisys has a consensus rating of “Hold” and a consensus price target of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.